461 Updated PFS analysis of toripalimab with anlotinib and chemotherapy as first-line therapy in patients with extensive-stage small-cell lung cancer (ES-SCLC)

• Hao Luo,
• Kan Gong,
• Liang Zhao,
• Dong Wang,
• Wei Guan,
• Mengxia Li,
• Li Zhong,
• Dan Jian,
• Shiheng Zhang,
• Jiamin Luo,
• Xueqin Yang,
• Yanli Xiong,
• Mingfang Xu,
• Yu Pu,
• Chengyuan Qian,
• Nan Dai

Affiliations

Hao Luo

Exercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia

Kan Gong

1 Department of Urology, Peking University First Hospital, Beijing, Beijing, China

Liang Zhao

Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital University of Medical Science, Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing, China

Dong Wang

Department of Neurology, Baogang Hospital of Inner Monglia, Inner Monglia, China

Wei Guan

Aff658 grid.418424.f0000000404392056Novartis Institutes for BioMedical Research, Inc Cambridge MA USA

Mengxia Li

Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China

Li Zhong

2Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian, China

Dan Jian

Cancer Center of Daping Hospital, Army Medical Center, Chongqing, China

Shiheng Zhang

Cancer Center of Daping Hospital, Army Medical Center, Chongqing, China

Jiamin Luo

Cancer Center of Daping Hospital, Army Medical Center, Chongqing, China

Xueqin Yang

Cancer Center of Daping Hospital, Army Medical Center, Chongqing, China

Yanli Xiong

Cancer Center of Daping Hospital, Army Medical Center, Chongqing, China

Mingfang Xu

Cancer Center of Daping Hospital, Army Medical Center, Chongqing, China

Yu Pu

Cancer Center of Daping Hospital, Army Medical Center, Chongqing, China

Chengyuan Qian

Cancer Center of Daping Hospital, Army Medical Center, Chongqing, China

Nan Dai

Cancer Center of Daping Hospital, Army Medical Center, Chongqing, China